Background Migraine is a cause of recurrent headaches in
H eadaches are a major cause of human have had at least one headache attack that disturbed daily activity. Headaches can be classified into two types, primary and secondary. Migraine and tension headaches have unknown pathologic mechanisms and are due to intrinsic conditions, such as brain tumors, elevated intracranial pressure, intoxication, sinusitis or acute conditions, such as influenza. 2 Migraine headaches are fairly common in the fifth most common disease in children. 3 The World Federation of Neurology stated that migraine is a familial disorder of recurrent headaches, with unilateral pulsating and varied intensity, frequency and duration. It is often accompanied by loss of appetite, nausea, and vomiting, but may be relieved by sleep. In some cases, it is also accompanied by emotional, neurological, visual, and autonomic disorders. 2, 3 Migraine treatment may be pharmacologic includes acute (abortive) and preventive (prophylactic) treatments. 4 Acute treatment aims treatment is given during a headache-free period, in order to decrease the frequency, duration, and intensity of migraines so that the patient will have improved quality of life and response to acute treatment. Both preventive and acute treatment may be given to people with heavy and frequent migraine attacks. children have been limited. However, several studies have recommended the use of adult medication in children with an adjusted dose. Beta blockers are generally the first line in preventing migraine, while amitriptyline is the second line. But some studies suggest using riboflavin for migraine prevention. Riboflavin is assumed to influence repair of mitochondrial dysfunction, which takes part in migraine pathophysiology. prevention in children have been limited in Indonesia, especially those pertaining to the administration of riboflavin. Riboflavin is relatively affordable and has minimal side effects (diarrhea and polyuria) compared to other medications. Therefore, we aimed to assess riboflavin effectiveness in prevention of migraine in adolescents. 
Placebo group (n=48)
Methods
We conducted a double-blind, randomized, controlled Musthafawiyah Mandailing Natal District, North month, causing impairment of daily activities, including those with contraindications or unresponsiveness to acute therapy, needing acute therapy more than twice weekly, and those with uncommon migraine, such as hemiplegic migraine or migraine with prolonged aura. We excluded subjects with chronic headaches and other medical conditions, such as neurological and psychiatric disorders, and those who had previously received preventive migraine therapy.
meeting the migraine criteria (with or without aura)
were examined before enrollment. We obtained data on frequency, intensity, and duration of migraines at height. This study was approved by the Medical Ethics day of riboflavin, while group II received a placebo.
supervised by teachers in taking their medications. At the beginning of study, we assessed migraine frequency, duration of headache, and disability using duration of headaches and side effects of medication. We collected diaries monthly. At the end of the third month, frequency, duration, and disability caused by migraine Chi square test was used to examine the association between dependent and independent was an intention-to-treat analysis.
Results
adolescents enrolled in the study (Figure 1) . (85) 0 (0) without aura. Food contributed to the occurrence of migraine attacks, such as coffee, chocolate, meat, instant noodles and other foods containing in both groups, 35.6 in the placebo group and 34.6 in the riboflavin group, most of whom were classified as having moderate disability ( Table 1) . Table 2 shows that migraine frequency in the first, second, and third months differed significantly between groups. Mean headache duration was not significantly different between groups in the first the duration was significantly shorter in riboflavin group compared to the placebo group at the second was significantly lower than that of the placebo group
Discussion
We found a reduction in frequency, duration, and disability of headache after three months of riboflavin treatment compared to the placebo in adolescents with migraine. The reductions in migraine frequency and pain duration were observed at the second and third months. Disability was also reduced after the third month.
Migraine headache is a familial condition with prevalences differing in age groups. The first step in diagnosing migraine is by screening for headache advice. A study in Bangkok, Thailand showed that We also found a high prevalence of migraine in
The reported incidence of migraine in schoolsuffering more frequently during adolescence and boys reportedly higher in girls (55%) than in boys (45%). We also found more girls than boys with migraines in our study. .4) 0 (0) 34 ( The cause of migraines is generally unknown. Only a few risk factors have been identified in children, that may lower the migraine threshold in children and adolescents are stress, menstrual periods, and foods such as chocolate and coffee. Another study showed with the condition. In our study, food contributed to the occurrence of migraine attack, with triggers including coffee, chocolate, meat, instant noodles and in both groups).
A study on migraines in Cincinnati showed headache types. A Finnish study showed an increased incidence of migraine with aura from 5.2
The majority without aura. If migraines occur once or twice monthly, prophylactic therapy is not needed. If migraines occur three or four times monthly, prophylactic therapy may be needed. If migraines occur more than five times monthly, prophylactic therapy is needed. Migraine prophylactic therapy is generally given to patients with frequent and disabling attacks. Average migraine duration in children is 2 to 4 hours, while that in We found the mean duration mean frequency of more than four times monthly. Riboflavin is the precursor of two coenzymes, flavin mononucleotide and flavin adenine dinucleotide. Both are involved in electron transport in oxidationencephalopathy, lactic acidosis and stroke-like episodes showed mitochondrial metabolism energy reduction, causing migraine-like headaches. In those subjects, headache was reduced by riboflavin treatment. The first study that evaluated riboflavin efficacy as of patients had a reduced number of migraines within 4 weeks of treatment. 23 We observed the administration of riboflavin over 3 months, revealing a reduction in migraine frequency at the second and third months of riboflavin treatment compared to placebo.
Beta blocker is the first line of migraine prophylactic treatment and amitriptyline is the second line. There have been few, limited studies using riboflavin for migraine prevention. Riboflavin is thought to influence the repairing of mitochondrial dysfunction that occurs in migraine pathophysiology.
A retrospective study in preventive effect, at low cost and minimal side effects. 23 For this reason, we used riboflavin in our study. A prospective study in Germany involving 23 daily for 6 months had reduced migraine attacks and decreased use abortive anti-migraine therapy. Another study in Belgium involving 26 migraine patients showed that riboflavin and beta blocker had similar efficacy in preventing migraine. The combination of these medications increased the efficacy. 24 In our study, we found significant reductions in frequency, duration, and disability after three months of riboflavin compared to placebo. Another trial in Belgium involving 54 subjects for 3 months showed that riboflavin was well tolerated and effective in preventing migraine, but subjects had diarrhea and polyuria as the side effects. 25 We also found diarrhea and polyuria to be side effects of riboflavin, though none of our subjects dropped out from the study.
and valid tool to evaluate disability due to headache in children and adolescents, with regards to functioning at school and daily home activities. One study showed as 22.3 points after prophylactic therapy. After reduced in the riboflavin group, but remained the same in the placebo group. Compared to placebo, riboflavin treatment showed reductions in migraine frequency in the second and third months, but was higher than that of the placebo group in the first month. Migraine duration in the first month was similar in both groups, but in second month, the duration decreased in the riboflavin group compared to that of the placebo group.
We concluded that riboflavin was well-tolerated and effective in reducing migraine frequency, duration, and disability in adolescents. Therefore, riboflavin may be used as migraine preventive therapy in adolescents.
